tirzepatide and increased heart rate Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Failure Tirzepatide, a dual GIP/GLP1-receptor co-agonist

Key takeaways Zepbound (tirzepatide) is a once-weekly injection approved to treat obesity and overweight, producing an average weight loss of up to 21% in clinical studies

The most compelling aspect of allulose is its ability to stimulate GLP-1 , a hormone that slows gastric emptying, reduces hunger, and improves insulin sensitivity

Yes, it is possible to switch from another GLP-1 medication to Zepbound

These establish your inflammatory baseline and help rule out other conditions driving elevated markers

The writing group has considered the rapid development of new treatments and technologies and addressed the following topics: diagnosis, aims of management, schedule of care, diabetes self-management education and support, glucose monitoring, insulin therapy, hypoglycaemia, behavioural considerations, psychosocial care, diabetic ketoacidosis, pancreas and islet transplantation, adjunctive therapies, special populations, inpatient management and future perspectives